Screening Using Portable Electronic Recorders for Sleep Apnea in Hypertensive At-Risk Populations (SUPER-SHARP Trial)
Study Details
Study Description
Brief Summary
Uncontrolled hypertension is associated with an increased risk of heart disease, stroke, and mortality. Obstructive sleep apnea (OSA) is common in hypertension and treatment using continuous positive airway pressure (CPAP) has been shown to effectively lower blood pressure. Despite its clinical significance, OSA remains underdiagnosed in patients with hypertension, because the current standard of care to diagnose OSA is in-laboratory polysomnography, which is inconvenient and often inaccessible for high-risk populations. An alternative to in-laboratory polysomnography is home sleep apnea testing, which has been validated against in-laboratory polysomnography and may be more convenient, accessible, and potentially cost-effective. The objective of this study is to compare home sleep apnea testing to in-laboratory polysomnography in a randomized controlled trial. We will assess whether the use of home sleep apnea testing, compared to use of in-laboratory polysomnography, leads to higher rates of OSA diagnosis and treatment using CPAP, a reduction in blood pressure, improved sleep-related outcomes, and greater patient satisfaction among patients with hypertension at 6 months. We will also assess whether home testing is cost-effective.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Home Sleep Apnea Test Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test. |
Device: Home Sleep Apnea Test
Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
Other Names:
|
| Active Comparator: In-laboratory Polysomnography Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography. |
Device: In-laboratory polysomnography
Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Diagnosis of OSA [6 months]
We will track the number of subjects in each arm who are diagnosed with OSA. Subjects who withdraw or are lost to follow-up without receiving a diagnosis of OSA will be included in our analysis as not having received an OSA diagnosis.
Secondary Outcome Measures
- Treatment using CPAP [6 months]
The proportion of patients treated for OSA using CPAP
- Change in 24-hour ambulatory blood pressure [6 months]
Change in 24-hour ambulatory blood pressure from baseline to 6 months
- Sleep-related quality of life (as assessed by the Functional Outcomes of Sleep Questionnaire) [6 months]
Sleep-related quality of life (as assessed by the Functional Outcomes of Sleep Questionnaire) at 6 months
- Daytime Sleepiness (as assessed by the Epworth Sleepiness Scale) [6 months]
Daytime Sleepiness (as assessed by the Epworth Sleepiness Scale) at 6 months
- Patient satisfaction with sleep testing [6 months]
Patient satisfaction for each strategy and treatment (as assessed by a Likert scale) at 6 months
Eligibility Criteria
Criteria
Inclusion Criteria:
-
(1) Hypertension, defined as:
-
uncontrolled blood pressure on or off medications, or
-
controlled blood pressure on 2 or more blood-pressure lowering medications
-
(2) At high risk for OSA:
-
STOP-BANG sleep apnea screening tool ≥3, or
-
Concomitant renal disease (estimated glomerular filtration rate [eGFR] 15-59), or
-
Resistant hypertension, defined as a blood pressure above target despite 3 or more BP-lowering drugs at optimal doses (preferably including a diuretic)
Exclusion Criteria:
- prior diagnosis of OSA, current use of CPAP, life expectancy less than 6 months, eGFR<15, gestational hypertension or preeclampsia, current use of dialysis, and physical/cognitive impairment/language barrier restricting the ability to complete the study assessments.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sunnybrook Health Sciences Centre | Toronto | Ontario | Canada | M4N3M5 |
| 2 | Women's College Hospital | Toronto | Ontario | Canada | M5S 1B2 |
Sponsors and Collaborators
- Sunnybrook Health Sciences Centre
- Women's College Hospital
Investigators
- Principal Investigator: Mark I Boulos, MD, MSc, University of Toronto and Sunnybrook Health Sciences Centre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5749